Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks. [PDF]
Fedorchenko SV +4 more
europepmc +1 more source
Structural bioinformatics approaches for predicting novel drug targets in hepatitis C virus proteins: a comprehensive analysis. [PDF]
Qu M +5 more
europepmc +1 more source
Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects. [PDF]
Wilfret DA +5 more
europepmc +1 more source
A key role for hepatitis C virus NS5A serine 225 phosphorylation revealed by super-resolution microscopy. [PDF]
Goonawardane N +4 more
europepmc +1 more source
Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease. [PDF]
Rothhaar P +29 more
europepmc +1 more source
Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies. [PDF]
Kumburegama BWMB +10 more
europepmc +1 more source
Strategies of Classical Swine Fever Immune Evasion. [PDF]
Zhang Y, Li F, Liu Y.
europepmc +1 more source
Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis. [PDF]
Inzaule S +16 more
europepmc +1 more source
Decoding microbial carcinogenic strategies: ubiquitination and SUMO modification. [PDF]
Liu Y, Zeng X, Lyu Z, Huang D.
europepmc +1 more source

